Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.57 |
| ▸ | F2 | P00734 | 13/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113759 | 0.79 | ALDH1A1 (0.48) | EPHX2HTR2CHTR2B | |
| SCHEMBL13874784 | 0.76 | EPHX2 (0.73) | EPHX2 | |
| SCHEMBL13873466 | 0.74 | EPHX2 (0.78) | EPHX2 | |
| SCHEMBL5471267 | 0.73 | MAPK8 (0.56) | EPHX2 | |
| SCHEMBL13873352 | 0.73 | EPHX2 (0.69) | EPHX2 | |
| SCHEMBL13873356 | 0.73 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL10058210 | 0.73 | F2 (0.63) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL14413547 | 0.73 | EPHX2 (0.76) | EPHX2 | |
| SCHEMBL6925911 | 0.72 | F2 (0.47) | EPHX2F2F10PRSS1PRSS2 | |
| SCHEMBL13873458 | 0.72 | EPHX2 (0.77) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | EPHX2 1735/4885F2 6/4885HTR2C 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.